Central Bank & Trust’s Emergent Biosolutions EBS Stock Holding History

Central Bank & Trust’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-496	Closed	-$3.38K	–	236
2024 Q2	$3.38K	Hold	496	–	–	﹤0.01%	344
2024 Q1	$1.25K	Hold	496	–	–	﹤0.01%	328
2023 Q4	$1.19K	Hold	496	–	–	﹤0.01%	343
2023 Q3	$1.69K	Sell	496 -125	-20%	-$693	﹤0.01%	323
2023 Q2	$4.56K	Hold	621	–	–	﹤0.01%	303
2023 Q1	$6.43K	Hold	621	–	–	﹤0.01%	298
2022 Q4	$7.33K	Hold	621	–	–	﹤0.01%	298
2022 Q3	$13K	Hold	621	–	–	﹤0.01%	266
2022 Q2	$19K	Sell	621 -14	-2%	-$478	﹤0.01%	260
2022 Q1	$26K	Sell	635 -392	-38%	-$17.3K	﹤0.01%	251
2021 Q4	$45K	Sell	1,027 -258	-20%	-$11.7K	0.01%	235
2021 Q3	$64K	Sell	1,285 -12,095	-90%	-$732K	0.01%	211
2021 Q2	$843K	Sell	13,380 -36,809	-73%	-$2.36M	0.14%	97
2021 Q1	$4.66M	Buy	50,189 +2,302	+5%	+$236K	0.8%	46
2020 Q4	$4.29M	Sell	47,887 -108	-0.2%	-$9.91K	0.74%	44
2020 Q3	$4.96M	Buy	47,995 +1,965	+4%	+$212K	0.93%	39
2020 Q2	$3.64M	Buy	+46,030	New	+$3.43M	0.72%	45

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Central Bank & Trust's EBS Position: Q3 2024 in Review

Central Bank & Trust sold out of Emergent Biosolutions (EBS) in Q3 2024, closing a stake of 496 shares — an estimated $3.38K sold.

Central Bank & Trust first reported a position in EBS in Q2 2020 and held it in 17 quarters. The position peaked at $4.96M in Q3 2020. 140 funds tracked by Wall St. Rank hold EBS as of Q3 2024.

Central Bank & Trust reported no remaining Emergent Biosolutions position as of Q3 2024 after selling out during the quarter.
Central Bank & Trust sold 496 Emergent Biosolutions shares in Q3 2024, an estimated $3.38K.
Central Bank & Trust first reported a position in Emergent Biosolutions in Q2 2020 and held it in 17 quarters.
Central Bank & Trust's Emergent Biosolutions position peaked at $4.96M in Q3 2020.
140 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2024.

Based on Central Bank & Trust's 13F filing for Q3 2024, filed 30 Oct 2024.